Study of Fluticasone Furoate/Vilanterol in COPD, and the effects of Reducing Lung Over-Inflation on the Heart

Mise à jour : Il y a 4 ans
Référence : EUCTR2012-000927-42

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The primary objective of the study is to test the hypothesis that lung hyperinflation contributes to cardiac dysfunction in COPD and that treatment of lung deflation with FF/VI Inhalation Powder 100/25 mcg administered once daily (QD) will result in the reversal of this cardiac dysfunction compared with placebo. This will be assessed by measures of right and left global and regional systolic and diastolic cardiac function as assessed using a 30 minute CMR.


Critère d'inclusion

  • Chronic Obstructive Pulmonary Disease (COPD)

Liens